Caris Life Sciences, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Caris adopted a form RSU award agreement for its 2025 Incentive Plan under which employees, consultants, and directors may receive restricted stock units vesting at the next annual shareholder meeting. The agreement specifies standard terms including perpetual confidentiality obligations, clawback provisions, Section 409A compliance, and a release-of-claims requirement. No specific grant amounts, participant names, or aggregate dilution are disclosed in this template document.
Why this rating
Template equity plan documentation is routine governance. No actual grants disclosed here—only the form. Material only when specific, large awards to named parties are announced.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.